Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome
| Autor: | Chantal Loirat, Gianluigi Ardissino, Franz Schaefer, Lisa Sartz, Anne-Laure Lapeyraque, Andrew M. Siedlecki, Miquel Blasco, Leena Martola, Daniel Landau, Masayo Ogawa, Véronique Frémeaux-Bacchi, Sally Johnson, Gema Ariceta, Michal Malina, Johan Vande Walle, Galina Generolova, Christoph J. Mache, David J. Cohen, Nicole M. Isbel, Fadi Fakhouri, Patricia Hirt-Minkowski, Christoph Gasteyger, Annick Massart, Eric Rondeau, Nicholas J.A. Webb, Jennifer James Eggleston, Larry A. Greenbaum, Natalya Lvovna Kozlovskaya, Marie Scully, Christoph Licht, Leonard Woodward, Donata Cresseri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
GENES medicine.medical_treatment 030232 urology & nephrology Renal function 030204 cardiovascular system & hematology urologic and male genital diseases Gastroenterology 03 medical and health sciences 0302 clinical medicine Clinical Research Internal medicine hemic and lymphatic diseases Atypical hemolytic uremic syndrome medicine Medicine and Health Sciences HUS RECURRENCE Kidney transplantation Dialysis OUTCOMES business.industry atypical hemolytic uremic syndrome Incidence (epidemiology) Hazard ratio kidney observational study Eculizumab medicine.disease EFFICACY Transplantation RECIPIENTS Nephrology SAFETY dialysis eculizumab business COMPLEMENT INHIBITOR ECULIZUMAB AHUS medicine.drug transplantation |
| Zdroj: | KIDNEY INTERNATIONAL REPORTS Kidney International Reports |
| ISSN: | 2468-0249 |
| Popis: | Introduction Recurrence of atypical hemolytic uremic syndrome (aHUS) in renal allografts is common, leading to dialysis and graft failure. Pretransplant versus posttransplant initiation of eculizumab treatment in patients with aHUS has not been rigorously investigated. We hypothesized eculizumab pretransplant would reduce dialysis incidence posttransplant. Methods Of patients enrolled in the Global aHUS Registry (n = 1549), 344 had ≥1 kidney transplant. Of these, 188 had received eculizumab. Eighty-eight patients (47%) were diagnosed with aHUS and received eculizumab before, and during, their most recent transplant (group 1). A total of 100 patients (53%; group 2) initiated eculizumab posttransplantation. This second group was subdivided into those diagnosed with aHUS before (n = 52; group 2a) or after (n = 48; group 2b) their most recent transplant. Results Within 5 years of transplantation, 47 patients required dialysis; the risk of dialysis after transplantation was significantly increased in group 2b (hazard ratio [HR] 4.6; confidence interval [CI] 1.7–12.4) but not 2a (HR 2.3; CI 0.9–6.2). Graft function within 6 months of transplantation was significantly better in group 1 (median estimated glomerular filtration rate of 60.6 ml/min per 1.73 m2) compared with 31.5 and 9.6 ml/min per 1.73 m2 in groups 2a (P = 0.004) and 2b (P = 0.0001), respectively. One meningococcal infection (resolved with treatment) and 3 deaths (deemed unrelated to eculizumab) were reported. Conclusions Outcomes for transplant patients with aHUS treated with eculizumab were improved compared with previous reports of patients with aHUS not treated with eculizumab. Our findings suggest delayed aHUS diagnosis and therefore treatment is associated with an increased risk of dialysis posttransplantation and reduced allograft function. Graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|